Brand Name Drugs news from FiercePharma
News
Study: Drug ads drown in online noise
Pharma marketing just got harder: A new study shows that patients are getting more information on meds from blogs and social-networking sites--places where drugmakers can't control their brand Read more...
ALSO NOTED: High-dose Celebrex triples heart risk; Actos slows plaque buildup in arteries;
> Patients taking the largest dose of Pfizer's painkiller Celebrex, 400 mg twice a day, tripled their chance of heart attack or stroke compared with placebo, according to a new study presented at Read more...
ALSO NOTED: Does FDA scrutinize new generics enough?; BMS shops baby-food business;
> Are generics as good as brand-name drugs? The Los Angeles Times questions the FDA's generic-approval process, which leans lightly on drug makers. Read more...
Pharma growth drops to 1961 levels
IMS Health is out with its new annual pharma sales report, and it ain't pretty. Revenue grew by only 3.8 percent to $286.5 billion, the slowest pace of expansion since 1961. By contrast, sales Read more...
Study: Costlier drug worked better
Here's some rock-and-a-hard-place news about drug costs. Drug makers raised prices by an average of 7.4 percent on the brand-name meds Read more...
States fight drug reps with reps
It's the case of the hair of the dog that bit you. Or perhaps a fight-fire-with-fire tactic. Either way, some states are employing their own pharma reps to combat Big Pharma's marketing machine. Take Read more...
Insurers pay docs for generic-switching
Maybe the folks probing drug company payments to docs should expand their field a bit. Now, health plans are drawing scrutiny for paying physicians to prescribe cheaper generics rather than Read more...
UK aims to slice drug prices 10%
A pharma nightmare with an English accent: The UK government wants to slash prices for prescription drugs by 10 percent. Sources told the Financial Times that officials are seeking a $2 billion-plus Read more...
Drug marketing costs double R&D
Every self-respecting pharma exec will tell you: R&D is the industry's peculiar burden, the chief reason why brand-name drugs are so expensive. But the average Joe or Jane consumer thinks that's, Read more...
Pharma growth sinking to historic low
Here's statistical confirmation of the gloom-and-doom facing Big Pharma. Worldwide sales growth will slow next year to around 5 Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets